- Conditions
- Arthroplasty, Replacement, Knee, Thromboembolism
- Interventions
- Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thromboembolism
- Interventions
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
- Conditions
- Thromboembolism
- Interventions
- Dabigatran, Warfarin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 12
- States / cities
- La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more
- Conditions
- Atrial Fibrillation
- Interventions
- dabigatran with ASA, warfarin, dabigatran without ASA
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 14
- States / cities
- Fayetteville, Arkansas • La Mesa, California • Pensacola, Florida + 11 more
- Conditions
- Thromboembolism
- Interventions
- Warfarin, Dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more